linjc16/ctgov huggingface dataset:
Single Versus Double Row Suture Anchor Repair in Medium to Large Rotator Cuff Tears

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether double row repair is better in healing than traditional single row repair in arthroscopic rotator cuff repair. Our null hypothesis is there are no differences in clinical and structural results

Official Title
-----------------
Prospective Randomized Case-controlled Blinded Study of Single Versus Double Row Suture Anchor Repair in Medium to Large Rotator Cuff Tears

Conditions
-----------------
Rotator Cuff Tear

Intervention / Treatment
-----------------
* Procedure: double row repair


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Rotator cuff tears tear size between 2cm 4cm Exclusion Criteria: Subscapularis tear requiring repair open repair any prior history of surgery on the affected shoulder any fracture history around shoulder girdle(clavicle, humerus, acromion) glenohumeral joint arthritis inflammatory arthropathy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: double row repair|double row repair for torn rotator cuff were performed to compare with the conventional single row repair|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retear rate in each group(single row repair group and double row repair group) |  | MRI after 6 months from surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rotator cuff tear, arthroscopic repair, single row repair, double row repair, retear rate
Evaluation of Surgical Positioning in Arthroscopic Shoulder Stabilization

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to prospectively determine whether intra-operative factors, complications and post-operative outcomes differ between beach chair and lateral decubitus surgical positioning for patients receiving arthroscopic shoulder stabilization (anterior or posterior) due to shoulder instability.

Official Title
-----------------
The Effects of Surgical Positioning on Arthroscopic Shoulder Stabilization: A Prospective Comparison

Conditions
-----------------
Shoulder Dislocation

Intervention / Treatment
-----------------
* Procedure: Beach Chair Position
* Procedure: Lateral Decubitus Position


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Any patient undergoing arthroscopic labral repair due to shoulder instability, with or without concomitant debridement. Exclusion Criteria: Revision stabilization surgery No previous Bankart repairs, labral repairs, capsulorrhaphy, or Latarjet Multidirectional shoulder instability Concomitant rotator cuff repair, biceps tenodesis/tenotomy, HAGL repair Isolated SLAP repair/labral repair in association with mechanism other than -instability (eg: overhead athletes) open procedures for instability

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Beach Chair<br>Patient positioned in beach chair position during arthroscopic shoulder stabilization | Procedure: Beach Chair Position<br>* Patients positioned in beach chair during arthroscopic shoulder stabilization<br>|
| Lateral decubitus<br>Patient positioned in lateral decubitus position during arthroscopic shoulder stabilization | Procedure: Lateral Decubitus Position<br>* Patients positioned in lateral decubitus position during arthroscopic shoulder stabilization<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Shoulder instability | Participants will be asked by their surgeon at routine follow up visits if they have encountered any episodes of shoulder instability (shoulder dislocations) | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative patient satisfaction | Participant satisfaction will be measured using the American Shoulder and Elbow Surgeons score (ASES) | 2 years | 
| Postoperative patient satisfaction | Participant satisfaction will be measured using the Single Assessment Numerical Evaluation survey (SANE) | 2 years | 
| Postoperative patient satisfaction | Participant satisfaction will be measured using the Western Ontario Shoulder Instability (WOSI) index | 2 years |
Resolving Grief After Spinal Cord Injury

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the usefulness of the Grief Recovery Method in assisting persons with spinal cord injuries to achieve as complete a recovery as possible, thereby allowing for fuller participation in life.

Official Title
-----------------
Resolving Grief and Moving On After Spinal Cord Injury

Conditions
-----------------
Spinal Cord Injury

Intervention / Treatment
-----------------
* Behavioral: The Grief Recovery Method


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: * Persons with a spinal cord injury who are willing to participate in the program. Exclusion Criteria: * Unable or unwilling to participate.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lifestyle counselling using the Grief Recovery Method<br>Volunteers will participate in a series of weekly and twice-weekly sessions with a counselor who has obtained special training in the Grief Recovery Method. | Behavioral: The Grief Recovery Method<br>* The Grief Recovery Method is a structured process designed to help people with spinal cord injuries examine their knowledge of their injury, their emotional reaction to their injury, and their ability to acknowledge their grief over the injury in order to learn techniques to resolve the grief in order to achieve a more complete recovery. Participants will attend a total of 18 sessions, some one-on-one, and some in a group setting. The Grief Recovery Handbook, handouts, DVD (digital video disc) presentations and questionnaires will be used. Targeted activities to decrease isolation and assist volunteers to identify goals for recovery will be utilized.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of Event Scale | A self-administered questionnaire with 22 questions designed to measure the subjective response to a specific traumatic event (for this study, the event is the spinal cord injury). | At Sessions 1 and 18. (Baseline and month 4) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Modified Grief Inventory | A self-reported 2-part questionnaire that asks the volunteer to circle responses to questions about past behavior and present feelings about their spinal cord injury. | At Sessions 1and 18 (baseline and month 4). | 
| The Coping with Health Injuries and Problems | A 32-question self-reported scale that measures coping with illness. | At sessions 1 and 18 (Baseline and month 4) |
Quality of Life Study of Helixate NexGen

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to describe Health Related Quality of Life (HRQoL) in adolescents and adults with Hemophilia A treated prophylactically or on-demand with Helixate NexGen. The study will also assess the kinds of determinants, including key transitional life events, that might impact HRQoL in this patient population.

Official Title
-----------------
A European, Prospective, Non-Interventional Study to Assess Health Related Quality of Life and to Identify Key Transitional Life Events in Patients With Moderate or Severe Haemophilia A Using Helixate NexGen

Conditions
-----------------
Hemophilia A

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Haemophilia A patient Severely (<1%) and moderately (1-5%) affected On treatment with Helixate NexGen Ability to read and understand study materials (patient information and data protection form, patient-related questionnaires) Signed data protection form; if patient is <18 years of age, legal guardian must also give written consent by signing the data protection form Exclusion Criteria: Presence of inhibitors Abuse of recreational drugs or alcohol interfering with the every-day-life in the opinion of the physician Advanced stage human immunodeficiency virus (HIV) infection (CD4 cell counts <200/cmm, multi-drug resistance, presence of AIDS related signs or symptoms) Symptomatic liver disease (cirrhosis, ascites, esophageal varices) Concomitant or planned interferon therapy Malignancies on or off treatment

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health Related Quality of Life (HRQoL) |  | baseline and every 12 months over 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in HRQoL due to pre-specified factors potentially affecting HRQoL in patients with hemophilia |  | Duration of the study | 
| Change in HRQoL due to transitional life events |  | Duration of the study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hemophilia, Quality of Life
Death Rate in Anesthesia, a Study in a Tertiary Hospital

Study Overview
=================
Brief Summary
-----------------
Death rate in anesthesia is one of the most valuable methods to assess the safety of anesthesia practice among different types of patients. In this study, the investigators will follow the death among patients who underwent surgery under anesthesia whether regional or general over the next two years from 2016 to 2018.

Detailed Description
-----------------
Death rate in anesthesia is one of the most valuable methods to assess the safety of anesthesia practice among different types of patients. Most of the studies of death rate in anesthesia are retrospective with many drawbacks and pitfalls like absence of information in the records of the patients. In this study, the investigators will follow the death among patients who underwent surgery under anesthesia whether regional or general over the next two years from 2016 to 2018, by examining the patients records from the hospital database and recording the events that occur to the dead patients. The end point of this study will be anesthesia death rate inside the hospital.

Official Title
-----------------
Death Rate in Anesthesia: a Prospective Study of Two Years Period From a Tertiary Hospital

Conditions
-----------------
Sudden Death

Intervention / Treatment
-----------------
* Other: anesthesia related deaths


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent anesthesia and surgery. Patients who died inside the hospital. Exclusion Criteria: Patient who underwent anesthesia and surgery and do not died and discharged home. Patients who died outside the hospital.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: anesthesia related deaths|number of anesthetized patients who died in the perioperative period inside the hospital|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of anesthetized patients who died in the perioperative period inside the hospital |  | 30 days post-operative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anesthesia
Effective Fraction of Inspired Oxygen With Nasal Cannula in Premature Infants

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to determine the multifactorial relationship between the effective fraction of inspired oxygen (Effective-FiO2) and the FiO2 in the gas delivered by the nasal cannula (NC-FiO2), NC flow rate, spontaneous minute ventilation and other patient characteristics in premature infants who receive supplemental oxygen via nasal cannula (NC).

Detailed Description
-----------------
During routine nasal cannula (NC) use in the newborn ICU, the actual fraction of oxygen inspired by the infant, i.e. the effective FiO2 (Effective-FiO2) that reaches the infant's airways, cannot be easily determined. The effective FiO2 during NC use is generally lower than the FiO2 in the gas delivered by NC at the infant's nose due to dilution with ambient gas entrained by the infants during spontaneous inspiration. The factors influencing effective FiO2 include the set FiO2 of the gas delivered by NC (NC-FiO2), the NC-flow rate, and the entrainment of ambient gas by the infant during each spontaneous inspiration. The individual contribution of each of these factors to the variability in effective-FiO2 in extreme premature infants has not been systematically evaluated. The objective of this study is to determine the multifactorial relationship between the effective fraction of inspired oxygen (Effective-FiO2) and the FiO2 in the gas delivered by the nasal cannula (NC-FiO2), NC flow rate, spontaneous minute ventilation and other patient characteristics in premature infants who receive supplemental oxygen via nasal cannula (NC).

Official Title
-----------------
Effective Fraction of Inspired Oxygen in Premature Infants Receiving Support Via Nasal Cannula

Conditions
-----------------
Oxygen Therapy

Intervention / Treatment
-----------------
* Other: Nasal cannula flow rate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Premature infants born between 23 and 30 weeks of gestational age Receiving supplemental oxygen via nasal cannula Parental informed consent Exclusion Criteria: Major congenital anomalies Clinically unstable
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Nasal cannula flow rate|This is a crossover study where observations will be obtained at five nasal cannula flow rates: 0.5, 1, 2, 4 and 6 liters per minute.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nasal cannula FiO2 | FiO2 necessary to maintain the effective FiO2 (measured at the hypopharynx) at the basal level at different nasal cannula flow rates. | from birth upto 40 weeks corrected postmenstrual age |
Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if it is safe and effective to give CPI-1189 to patients with AIDS dementia. Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.

Detailed Description
-----------------
Late-stage HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down. Patients are randomized to receive either placebo or one of two oral doses of CPI-1189 daily. Patients are assessed for safety and tolerability during Weeks 2, 6, and 10. At Week 10, efficacy assessments are also made. For those who volunteer, a sample of cerebrospinal fluid is obtained at baseline and at Week 10. Blood samples for CPI-1189 pharmacokinetic trough measurements are taken at Weeks 2 and 10. The open-label phase starts at Week 11. At Weeks 13 and 16, a safety evaluation is performed. At the end of the open-label phase, Week 22, a final set of safety and efficacy assessments and a blood sample for CPI-1189 pharmacokinetic trough measurement are obtained.

Official Title
-----------------
Randomized, Double-Blind, Parallel Group, Placebo Controlled, Tolerability, Safety and Pilot Efficacy Study of CPI-1189 in HIV Infected Individuals With Cognitive and Motor Impairment

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: CPI-1189


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria You may be eligible for this study if you: Are HIV-positive. Are at least 18 years old. Have symptoms of AIDS dementia including forgetfulness, loss of concentration, slow mental processing, or a loss of muscle control. Have been on stable anti-HIV drug therapy for the past 6 weeks (if you are taking anti-HIV drugs). Exclusion Criteria You will not be eligible for this study if you: Have certain serious medical conditions, such as a mental disorder or an opportunistic (AIDS-related) infection.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: CPI-1189|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AIDS Dementia Complex, Anti-HIV Agents
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with plaque-type psoriasis.

Detailed Description
-----------------
The purpose of this study is to investigate the safety and possible usefulness of infliximab therapy for patients with severe plaque psoriasis. In a previous small study of infliximab in 33 patients with psoriasis, about 80% of patients treated with infliximab showed improvement in their psoriasis symptoms after the first 3 infusions, while 20% of patients who received placebo showed improvement. The patients will receive infusions of infliximab either 3 or 5 mg/kg or placebo at weeks 0,2,6. Patients who have significant psoriasis at week 26 will receive an additional infusion.

Official Title
-----------------
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab (REMICADE�) Induction Therapy in Patients With Plaque-type Psoriasis

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Drug: infliximab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be 18 years of age or older at time of enrollment may be male or female Have had a diagnosis of plaque-type psoriasis at least 6 months prior to screening Have plaque-type psoriasis covering at least 10% of total BSA at baseline Have previously received PUVA and/or other systemic treatment for psoriasis Exclusion Criteria: Have non-plaque forms of psoriasis Have a history of drug-induced psoriasis Are pregnant, nursing, or planning pregnancy within 12 months of enrollment Have had any previous treatment with infliximab or any therapeutic agent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: infliximab|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients achieving a = 75% improvement in PASI score from baseline at week 10 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The proportion of patients positive for antibodies to infliximab;The proportion of patients with infusion reactions at week 26;The proportion of infliximab-treated patients with infusion reaction at week 26 by antibodies to infliximab status at week 26 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Plaque-type Psoriasis, infliximab, Remicade, biologics